What's Happening?
Moderna, Inc. has been the focus of multiple analyst reports following its recent earnings announcement and ongoing cost-cutting strategies. UBS has highlighted potential upside for 2026 due to pipeline
developments and expense management, while Redburn Atlantic has reduced its price target to $36, maintaining a neutral rating. Bernstein has reiterated a market perform stance with a $25 price target, emphasizing the importance of cost reductions to avoid the need for external capital. Moderna's stock traded higher during the U.S. session, reflecting mixed but stabilizing investor sentiment.
Why It's Important?
The analyst revisions and cost-cutting measures are significant as they reflect the market's response to Moderna's strategic adjustments in a challenging environment. The company's ability to manage expenses and focus on its pipeline could position it for future growth, particularly as demand for COVID and RSV vaccines remains subdued. The mixed analyst outlook underscores the uncertainty surrounding Moderna's financial trajectory, with cost management being a critical factor for achieving cash breakeven by 2028.
What's Next?
Investors will be watching for further clarity on Moderna's regulatory path for its COVID/flu combination vaccine and any progress in its late-stage assets, such as the mRNA-4157 therapy. The upcoming International mRNA Health Conference may also provide insights into the broader mRNA technology landscape, potentially influencing Moderna's strategic direction and investor sentiment.
